The improvements in stent flexibility and biocompatibility have lead to the conclusion by Dr. Mitchell Krucoff that second-generation drug eluting-stents, such as Abbott's Xience stent, result in an improved ability to prevent restenosis following angioplasty and stent implantation. See an excerpt from India's pharmabiz.com (which also highlights the market potential for coronary stents in India): [...]
Drug-eluting stents were developed to release a drug (e.g., sirolimus or paclitaxel) intended to reduce the incidence of restenosis. From there, even more innovative products have been developed, such as bioactive stents or stents designed to attract a patient’s own endothelial cells to coat the stent (as in devices by OrbusNeich, Hexacath, and Miami Cardiovascular [...]
Below is an excerpt from the April 2009 Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017." The materials used in coronary stents must be flexible, supportive, capable of expansion, and biocompatible. Typically, foreign materials implanted into the human body results in trauma, inflammation, immune response and eventual healing and/or scarring. Materials [...]
The worldwide market for drug-eluting, as well as bare, bioresorbable and other stents, is now the subject of the May 2009 report by MedMarket Diligence, Report #C245. Below is an excerpt from MedMarket Diligence’s coverage of the drug-eluting stents market in mid-2008. The previous scarcity of long term data left some uncertainty about DES’ clinical and [...]
Contact:
